Xortx Therapeutics Inc (XRTX)

$0.50 +0.01 (2.53%)
Market Cap 3.48M
Revenue (ttm) 0.00
Net Income (ttm) -3.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,100
Avg Vol 44,986
Day's Range N/A - N/A
Shares Out 6.96M
Stochastic %K 33%
Beta 0.49
Analysts Strong Buy
Price Target $14.00

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, w...

Industry: Biotechnology
Sector: Healthcare
Phone: 403 455 7727
Address:
3710 – 33rd Street NW, Calgary, Canada
stockflyer88
stockflyer88 Feb. 3 at 5:43 PM
$XRTX let's go 🚀
0 · Reply
Joshimi
Joshimi Feb. 3 at 3:56 PM
$XRTX
0 · Reply
LookaLike
LookaLike Jan. 30 at 1:58 PM
$XRTX where did you read the news about the Webinar? Was there a PR?
1 · Reply
honestrick
honestrick Jan. 29 at 10:29 PM
$XRTX Why is the webinar cancelled again? I e-mailed Dr Davidoff ;Im sure I wont get a reply If anyone cares enough please contact them .They need to put out some kind of a release .
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 21 at 1:07 AM
$XRTX RSI: 40.69, MACD: -0.0073 Vol: 0.02, MA20: 0.58, MA50: 0.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
honestrick
honestrick Jan. 20 at 7:52 PM
$SEGG Want to make your $$$$ back ,Look at $XRTX they have a Webinar tommorrow after the close ..I think the low has been made ..Buy today or after the Webinar ,I also think $ADTX has finished with there tricks and its time to roar up ..Both are low floats .. GLTA with your SEGG TRADE .
0 · Reply
spikespants
spikespants Jan. 15 at 1:42 AM
$XRTX spike and drop on October 17. What is happening with this binding term sheet with Vectus Biosystems? No news since then. I'm in at .88
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jan. 12 at 1:28 AM
Small-Cap with Catalysts this week: 👇👇 ( $AUUD, $XRTX, $OFAL, $LGVN, $ENVB, etc...) #NASDAQ #NYSE
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 3:19 AM
$XRTX Current Stock Price: $0.56
0 · Reply
warm_it_up
warm_it_up Jan. 2 at 12:44 AM
$XRTX https://www.xortx.com/news/press-releases/detail/193/xortx-announces-pioneering-research-on-genome-wide More of this please!
0 · Reply
Latest News on XRTX
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 3 months ago

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Oct 20, 2025, 8:34 PM EDT - 3 months ago

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Oct 20, 2025, 6:45 PM EDT - 3 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Oct 17, 2025, 7:00 AM EDT - 3 months ago

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Sep 3, 2025, 7:00 AM EDT - 5 months ago

XORTX Initiates IND Preparation for XORLO™ in Gout Program

XORTX Completes USD $114,500 Private Placement

Aug 8, 2025, 7:54 PM EDT - 6 months ago

XORTX Completes USD $114,500 Private Placement

XORTX Completes Non-Brokered Private Placement of Units

Jul 22, 2025, 7:59 PM EDT - 7 months ago

XORTX Completes Non-Brokered Private Placement of Units

XORTX Announces USD $925,000 Private Placement

Jun 26, 2025, 7:00 AM EDT - 7 months ago

XORTX Announces USD $925,000 Private Placement

XORTX Announces USD $3 Million Offering

May 19, 2025, 7:00 AM EDT - 9 months ago

XORTX Announces USD $3 Million Offering

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:45 PM EDT - 10 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Announces Change of Auditor

Jan 17, 2025, 5:00 PM EST - 1 year ago

XORTX Announces Change of Auditor

XORTX Announces Presentation at the Rare and Genetic Disease Summit

Dec 12, 2024, 9:17 AM EST - 1 year ago

XORTX Announces Presentation at the Rare and Genetic Disease Summit

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 18, 2024, 4:00 PM EDT - 1 year ago

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Initiates Precision Medicine Program

Oct 9, 2024, 5:00 AM EDT - 1 year ago

XORTX Initiates Precision Medicine Program

XORTX Announces Results of Annual and Special Meeting of Shareholders

Sep 13, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

Sep 12, 2024, 5:30 PM EDT - 1 year ago

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Sep 6, 2024, 5:30 PM EDT - 1 year ago

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Sep 3, 2024, 12:30 PM EDT - 1 year ago

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

Aug 23, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

May 17, 2024, 7:00 AM EDT - 1 year ago

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Apr 30, 2024, 1:54 PM EDT - 1 year ago

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

XORTX Announces Publication of Key Research in ADPKD

Apr 22, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Publication of Key Research in ADPKD

XORTX Welcomes New Member to the Board of Directors

Apr 8, 2024, 7:30 AM EDT - 1 year ago

XORTX Welcomes New Member to the Board of Directors

XORTX Announces New Clinical Advisory Board Member

Mar 27, 2024, 5:00 AM EDT - 2 years ago

XORTX Announces New Clinical Advisory Board Member

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Mar 19, 2024, 5:00 AM EDT - 2 years ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Mar 4, 2024, 7:00 AM EST - 2 years ago

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

Feb 1, 2024, 8:46 PM EST - 2 years ago

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

XORTX Announces $2 Million Public Offering

Jan 15, 2024, 7:00 AM EST - 2 years ago

XORTX Announces $2 Million Public Offering

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Jan 3, 2024, 7:00 AM EST - 2 years ago

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

XORTX Announces US ATM Offering

Nov 30, 2023, 7:30 AM EST - 2 years ago

XORTX Announces US ATM Offering

XORTX Meets Nasdaq Continued Listing Requirements

Nov 29, 2023, 7:00 AM EST - 2 years ago

XORTX Meets Nasdaq Continued Listing Requirements

XORTX Clarifies Timing for Share Consolidation

Nov 10, 2023, 7:00 AM EST - 2 years ago

XORTX Clarifies Timing for Share Consolidation

XORTX Announces Share Consolidation

Nov 8, 2023, 5:00 PM EST - 2 years ago

XORTX Announces Share Consolidation

XORTX Announces Results of Special Meeting of Shareholders

Oct 27, 2023, 5:30 PM EDT - 2 years ago

XORTX Announces Results of Special Meeting of Shareholders

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023, 5:00 PM EDT - 2 years ago

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 25, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces Rescheduling of Special Meeting of Shareholders

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 12, 2023, 7:00 AM EDT - 2 years ago

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

XORTX Calls Special Meeting of Shareholders

Oct 4, 2023, 7:00 AM EDT - 2 years ago

XORTX Calls Special Meeting of Shareholders

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

Aug 29, 2023, 7:00 AM EDT - 2 years ago

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

XORTX Appoints Chief Financial Officer

Aug 4, 2023, 5:00 PM EDT - 2 years ago

XORTX Appoints Chief Financial Officer

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

Jun 23, 2023, 8:51 PM EDT - 2 years ago

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

May 24, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

Apr 21, 2023, 7:00 AM EDT - 3 years ago

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Feb 1, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

Jan 19, 2023, 7:00 AM EST - 3 years ago

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dec 8, 2022, 7:00 AM EST - 3 years ago

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

Nov 28, 2022, 7:00 AM EST - 3 years ago

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

Nov 16, 2022, 7:00 AM EST - 3 years ago

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

XORTX Presents New Proof of Concept Data at American Society of Nephrology

Nov 3, 2022, 5:00 PM EDT - 3 years ago

XORTX Presents New Proof of Concept Data at American Society of Nephrology

stockflyer88
stockflyer88 Feb. 3 at 5:43 PM
$XRTX let's go 🚀
0 · Reply
Joshimi
Joshimi Feb. 3 at 3:56 PM
$XRTX
0 · Reply
LookaLike
LookaLike Jan. 30 at 1:58 PM
$XRTX where did you read the news about the Webinar? Was there a PR?
1 · Reply
honestrick
honestrick Jan. 29 at 10:29 PM
$XRTX Why is the webinar cancelled again? I e-mailed Dr Davidoff ;Im sure I wont get a reply If anyone cares enough please contact them .They need to put out some kind of a release .
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 21 at 1:07 AM
$XRTX RSI: 40.69, MACD: -0.0073 Vol: 0.02, MA20: 0.58, MA50: 0.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
honestrick
honestrick Jan. 20 at 7:52 PM
$SEGG Want to make your $$$$ back ,Look at $XRTX they have a Webinar tommorrow after the close ..I think the low has been made ..Buy today or after the Webinar ,I also think $ADTX has finished with there tricks and its time to roar up ..Both are low floats .. GLTA with your SEGG TRADE .
0 · Reply
spikespants
spikespants Jan. 15 at 1:42 AM
$XRTX spike and drop on October 17. What is happening with this binding term sheet with Vectus Biosystems? No news since then. I'm in at .88
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jan. 12 at 1:28 AM
Small-Cap with Catalysts this week: 👇👇 ( $AUUD, $XRTX, $OFAL, $LGVN, $ENVB, etc...) #NASDAQ #NYSE
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 3:19 AM
$XRTX Current Stock Price: $0.56
0 · Reply
warm_it_up
warm_it_up Jan. 2 at 12:44 AM
$XRTX https://www.xortx.com/news/press-releases/detail/193/xortx-announces-pioneering-research-on-genome-wide More of this please!
0 · Reply
honestrick
honestrick Dec. 31 at 4:15 PM
$SIDU Help a guy out. If everyone just sold 10% and bought $XRTX it will go up in Jan 2026 after the webcast , You will make me very happy . Ok... I can dream . GLTA ...
0 · Reply
honestrick
honestrick Dec. 29 at 6:33 PM
$XRTX Dont blink .
0 · Reply
warm_it_up
warm_it_up Dec. 29 at 2:14 AM
$XRTX I had a dream that I woke up and this was $3. A guy can dream.
0 · Reply
spikespants
spikespants Dec. 29 at 12:00 AM
$SAFX $AIIO $XRTX strange ambiguous posts from multiple accounts with different names... All of them only have one single post.
0 · Reply
EvolutionExpert
EvolutionExpert Dec. 26 at 12:32 PM
$XRTX The environment increasingly favors disciplined operators instead of aggressive storytellers. Improving execution cadence across quarters would alter sentiment materially. Confidence weakens if progress becomes episodic rather than consistent. Execution quality will determine whether momentum is sustainable.
0 · Reply
Joshimi
Joshimi Dec. 22 at 3:43 PM
$XRTX
0 · Reply
honestrick
honestrick Dec. 14 at 1:43 AM
$XRTX Webinar for $XRTX on Jan21,2026 at 4.15 pm is a good sign. Jan is usually the start of good things for a stock . Looking for a move up and a continue after the webinar .$DRUG $CGC $BB
0 · Reply
LookaLike
LookaLike Dec. 10 at 5:57 PM
$XRTX of you see the timelines of smallcap biotech stock dont take it seriously. 6-12 months mostly means 12-24 months or more
0 · Reply
andysch
andysch Dec. 8 at 5:16 PM
$XRTX …this week or next!? Opinions…
0 · Reply
andysch
andysch Dec. 4 at 6:40 PM
$XRTX When IND!?
0 · Reply
honestrick
honestrick Nov. 28 at 4:29 PM
$XRTX If you want my 200,000 shares, you have to try a lot harder. GLTA .
0 · Reply
honestrick
honestrick Nov. 25 at 3:36 PM
$XRTX test
0 · Reply